Detalles de la búsqueda
1.
Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Cancer
; 122(20): 3119-3126, 2016 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27412268
2.
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Eur Respir J
; 48(3): 861-72, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27338193
3.
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 16(15): 1493-1505, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26474518
4.
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.
Eur Respir J
; 43(1): 240-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24114964
5.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(2): 149-58, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23306100
6.
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients.
Eur J Pharm Sci
; 199: 106809, 2024 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38788907
7.
A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.
Support Care Cancer
; 21(7): 1947-54, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23420555
8.
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Lancet
; 378(9796): 1079-88, 2011 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-21831418
9.
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.
Lung Cancer
; 164: 84-90, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35051725
10.
Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts.
Cancers (Basel)
; 13(24)2021 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34944774
11.
Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).
J Clin Oncol
; 38(15): 1702-1710, 2020 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32167864
12.
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
J Thorac Oncol
; 15(4): 628-636, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31945494
13.
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
Eur J Cancer
; 138: 193-201, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32898792
14.
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
Cancer Med
; 8(11): 5079-5088, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31314957
15.
Effects of a physical activity programme to prevent physical performance decline in onco-geriatric patients: a randomized multicentre trial.
J Cachexia Sarcopenia Muscle
; 10(2): 287-297, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30829460
16.
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as firstline therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
Int J Oncol
; 54(4): 1433-1445, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30720091
17.
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
J Clin Oncol
; 36(15): 1469-1477, 2018 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29620995
18.
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Eur Urol
; 73(5): 696-703, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29074061
19.
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Lancet Gastroenterol Hepatol
; 2(5): 337-346, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28397697
20.
Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Eur J Cancer
; 54: 69-74, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26724422